- Home
- IPHA vs CGEN Comparison
IPHA vs CGEN Comparison
Compare IPHA & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPHA | CGEN |
|---|---|---|
| Founded | 1999 | 1993 |
| Country | France | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.6M | 148.7M |
| IPO Year | 2019 | 2000 |
Fundamental Metrics
Financial Performance| Metric | IPHA | CGEN |
|---|---|---|
| Price | $1.71 | $1.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $5.00 | $4.00 |
| AVG Volume (30 Days) | 18.3K | ★ 549.7K |
| Earning Date | 03-26-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,839,695.00 | $6,903,000.00 |
| Revenue This Year | $22.29 | N/A |
| Revenue Next Year | $43.90 | $164.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.63 | $1.13 |
| 52 Week High | $2.63 | $2.66 |
Technical Indicators
Market Signals| Indicator | IPHA | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 37.53 |
| Support Level | N/A | $1.58 |
| Resistance Level | N/A | $2.08 |
| Average True Range (ATR) | 0.00 | 0.10 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 0.00 | 3.75 |
Price Performance
Historical ComparisonAbout IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.